Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Duloxetine Hydrochloride
Therapeutic Area : Musculoskeletal
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Duloxetine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Osteoarthritis, Knee.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 21, 2024
Lead Product(s) : Duloxetine Hydrochloride
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Duloxetine Hydrochloride
Therapeutic Area : Undisclosed
Study Phase : Phase IV
Sponsor : Central Denmark Region | University of Aarhus | Vejle Hospital | Aalborg University | TrygFonden | Independent Research Fund Denmark
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Duloxetine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 30, 2024
Lead Product(s) : Duloxetine Hydrochloride
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Sponsor : Central Denmark Region | University of Aarhus | Vejle Hospital | Aalborg University | TrygFonden | Independent Research Fund Denmark
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Esketamine Hydrochloride,Duloxetine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Spravato® (esketamine) is the S-enantiomer of racemic ketamine and is a non-selective, non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, an ionotropic glutamate receptor. It is being developed for treating resistant major depressiv...
Product Name : Spravato
Product Type : Controlled Substance
Upfront Cash : Inapplicable
November 23, 2022
Lead Product(s) : Esketamine Hydrochloride,Duloxetine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Duloxetine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Duloxetine Impact on Postoperative Pain Control and Outcomes
Details : Duloxetine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Pain, Postoperative.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 10, 2022
Lead Product(s) : Duloxetine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Duloxetine Hydrochloride
Therapeutic Area : Musculoskeletal
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Biomarkers for Prediction of Analgesic Efficacy in Knee OA.
Details : Duloxetine is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Osteoarthritis, Knee.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 25, 2022
Lead Product(s) : Duloxetine Hydrochloride
Therapeutic Area : Musculoskeletal
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Duloxetine Hydrochloride
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioavailability of Duloxetine 60 mg With Regards to Reference Product in Feeding Conditions
Details : Duloxetine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 12, 2021
Lead Product(s) : Duloxetine Hydrochloride
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Duloxetine Hydrochloride
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioavailability of Duloxetine 60 mg With Regards to Reference Product in Fasting Conditions
Details : Duloxetine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 25, 2021
Lead Product(s) : Duloxetine Hydrochloride
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Duloxetine Hydrochloride
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : National Institute of Arthritis and Musculoskeletal and Skin Diseases | Pacira BioSciences
Deal Size : Inapplicable
Deal Type : Inapplicable
A Sequenced Strategy for Improving Outcomes in People With Knee Osteoarthritis Pain
Details : Duloxetine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Osteoarthritis, Knee.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 07, 2020
Lead Product(s) : Duloxetine Hydrochloride
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : National Institute of Arthritis and Musculoskeletal and Skin Diseases | Pacira BioSciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Esketamine Hydrochloride,Duloxetine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
(n)SPRAVATO® (esketamine)* Nasal Spray is Available for Canadian Patients
Details : Spravato® (esketamine) is the S-enantiomer of racemic ketamine and is a non-selective, non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, an ionotropic glutamate receptor. It is being developed for treating resistant major depressiv...
Product Name : Spravato
Product Type : Controlled Substance
Upfront Cash : Inapplicable
July 22, 2020
Lead Product(s) : Esketamine Hydrochloride,Duloxetine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Duloxetine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Duloxetine hydrochloride is a serotonin and norepinephrine reuptake inhibitor (SNRI) and the delayed-release capsules, for oral use, were first approved in the U.S. in 2004.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 08, 2020
Lead Product(s) : Duloxetine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable